FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Antibodies topics
Antibodies
Recombinant
Nucleic Acid
Nucleic Acids
Polypeptide
Therapeutics
Immunoglobulin
Immunoglobulins
Monoclonal
Radiation Therapy
Desmoplastic
Hypertension
Hypertensive
Immunotherapy
Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antibodies patents



      
           
This page is updated frequently with new Antibodies-related patent applications. Subscribe to the Antibodies RSS feed to automatically get the update: related Antibodies RSS feeds. RSS updates for this page: Antibodies RSS RSS


Date/App# patent app List of recent Antibodies-related patents
04/16/15
20150104866
 Ip-10 antibodies and their uses patent thumbnailnew patent Ip-10 antibodies and their uses
The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to ip-10 with high affinity, inhibit the binding of ip-10 to its receptor, inhibit ip-10-induced calcium flux and inhibit ip-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Medarex, L.l.c.
04/16/15
20150104831
 Antibodies and uses thereof patent thumbnailnew patent Antibodies and uses thereof
The present invention provides antibodies which bind to an epitope in the extracellular domain of human cc chemokine receptor 4 (ccr4) and which are capable of inhibiting the binding of macrophage-derived chemokine (mdc) and/or thymus and activation regulated chemokine (tarc) to ccr4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields..
Affitech Research As
04/16/15
20150104818
 Gemcitabine immunoassay patent thumbnailnew patent Gemcitabine immunoassay
The present invention comprises novel conjugates and immunogens derived from gemcitabine and unique antibodies generated by using gemcitabine linked immunogens, which conjugates immunogens and antibodies, are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids.. .
Saladax Biomedical Inc.
04/16/15
20150104817
 Hydroxycholesterol immunoassay patent thumbnailnew patent Hydroxycholesterol immunoassay
Provided is a derivative of 22-hydroxycholesterol, 24s-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative.
Enzo Life Sciences, Inc. C/o Enzo Biochem, Inc.
04/16/15
20150104473
 Adjuvant compound patent thumbnailnew patent Adjuvant compound
The invention is directed to a compound according to the formula [1] wherein r1 and r2 are branched or straight groups having up to 17 atoms selected from carbon, nitrogen, oxygen and sulphur, n is 0 to and including 18, y is sulphur or selene, x is s or 0 and r is —oh or an organic group comprising one or more peptides, one or more nucleic acids, one or more antibodies or combinations thereof. The invention is also directed to process for preparing said compound and the use of said compound as an adjuvant.
Isa Pharmaceuticals B.v.
04/16/15
20150104468
 Site-specific labeling methods and molecules produced thereby patent thumbnailnew patent Site-specific labeling methods and molecules produced thereby
The present disclosure provides methods of site-specific labeling of antibodies, using proteins having 4′-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates..
Irm Llc
04/16/15
20150104466
 Cytomegalovirus disintegrin-like peptides patent thumbnailnew patent Cytomegalovirus disintegrin-like peptides
The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gb disintegrin-like domain has been identified that engages integrins and facilitates viral internalization into the host cell.
Wisconsin Alumni Research Foundation
04/16/15
20150104464
 Monoclonal antibody therapy for pancreas cancer patent thumbnailnew patent Monoclonal antibody therapy for pancreas cancer
The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.. .
Precision Biologics, Inc.
04/16/15
20150104461
 Anti-notch2 nrr antibodies patent thumbnailnew patent Anti-notch2 nrr antibodies
The invention provides anti-notch antibodies, and in particular, antibodies that bind notch2 nrr, and methods of using the same.. .
Genentech, Inc.
04/16/15
20150104460
 Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions patent thumbnailnew patent Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions
Specific binding members, particularly human antibodies, particularly recombinant antibodies, and fragments thereof, which are capable of binding to and recognizing neurons in the cns and eliciting responses in cns neurons are provided. The antibodies are useful in the diagnosis and treatment of conditions associated with nerve damage, injury or degeneration and neurodegenerative disease, and in particular in the treatment or alleviation of stroke or cerebral ischemia.
Mayo Foundation For Medical Education And Research
04/16/15
20150104459
new patent

Compositions and methods for the therapy and diagnosis of influenza


The present invention provides compositions, vaccines, and methods for diagnosing, treating, and preventing influenza infection using a combination of antibodies raised against the influenza hemagglutinin and the matrix 2 ectodomain polypeptides.. .
Theraclone Sciences, Inc.
04/16/15
20150104457
new patent

Il-17 antagonist antibodies


The disclosure relates to antibodies against human il-17 which act as antagonist antagonists of il-17, and their use in the diagnosis or treatment of il-17 mediated diseases.. .
Orega Biotech
04/16/15
20150104454
new patent

Anti-c.difficile toxin antibodies and associated methods


Embodiments of the invention are directed to a composition comprising a recombinant protein in soluble form wherein said recombinant protein comprises a portion of the clostridium difficile toxin b sequence that comprises an epitope for anti-toxin b antibody. Other embodiments of the invention are directed to the generation of antibodies using peptide fragments of c.
Board Of Regents Of The University Of Oklahoma
04/16/15
20150104453
new patent

Fdf03 antibodies and uses thereof


The present invention relates to methods for identifying and using modulators of fdf03 biological activity in vitro and in vivo that are useful in the treatment of cancer.. .
Merck Sharp & Dohme Corp.
04/16/15
20150104448
new patent

Anti-complement c1s antibodies and uses thereof


The present disclosure provides antibodies that bind complement c1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions..
True North Therapeutics, Inc.
04/16/15
20150104409
new patent

Human monoclonal antibodies to ctla-4


In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic t-lymphocyte antigen 4 (ctla-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (cdrs), specifically from within fr1 and/or cdr1 through cdr3 and/or within fr4, are provided.
Pfizer Inc.
04/09/15
20150100030

Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies


The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hil-4r). The formulations may contain, in addition to an anti-hil-4r antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant.
Regeneron Pharmaceuticals, Inc.
04/09/15
20150099864

Preparation of organophosphate peptide adducts


Disclosed are methods for the synthesis of organophosphorus-adducted peptides. Such peptides may be useful as biomarkers of organophosphate exposure, or for the synthesis of antibodies.
Battelle Memorial Institute
04/09/15
20150099862

Novel human control antibodies and uses therefor


The present invention provides novel, rationally designed human control antibodies for use in various in vivo and in vitro applications. The antibodies of the present invention have well characterized variable domains that have been designed to minimize or eliminate antigen binding without altering gross antibody structure.
Ab Biosciences, Inc.
04/09/15
20150099861

Anti alphabetatcr antibody


The present invention relates to humanized monoclonal antibodies comprising the cdrs of murine antibody bma031, which bind to the aptcr.cd3 complex and possess improved biological properties.. .
Genzyme Corporation
04/09/15
20150099656

Multiplex immuno screening assay


The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients.
Institut Pasteur
04/09/15
20150099652

In vitro process for the quick determination of a patient's status relating to infection with mycobacterium tuberculosis


An in-vitro process for the quick determination of the infection status of a mycobacterium tuberculosis infection from whole blood in terms of active or latent tuberculosis, comprising the steps of: stimulating an antigen-specific t cell that is present in a first sample of whole blood with purified protein derivative (ppd) in the presence of antibodies against cd28, or cd28 and cd49d; processing of ppd by antigen-presenting coils (apc) by incubating for 1.5 h to 2.5 h, especially for 2 h, at 35° c. To 39° c., especially at 37° c., optionally with raiding c02; then adding a secretion inhibitor; effecting an intensive mixing; and another incubation for a period of at least 2.5 h at a temperature of from 35° c.
Red Flag Diagnostics Gmbh
04/09/15
20150099636

Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex


The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.
Intrexon Corporation
04/09/15
20150099302

Clonal expansion of b cells


The present invention provides recombinant proteins comprising the amino acid sequence of an intracellular segment of cd40 and an amino acid sequence mediating the association of the recombinant protein with the constant region of an immunoglobulin heavy chain. The recombinant proteins according to the present invention are useful for inducing clonal expansion of a b cell having a predetermined antigen-specificity without the need for t cell or cd40l mediated co-stimulation.
Universitatsmedizin Der Johannes Gutenberg-universitat Mainz
04/09/15
20150099298

Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof


The present invention relates to antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.. .
Bayer Pharma Aktiengesellschaft
04/09/15
20150099295

Recombinant production of authentic human proteins using human cell expression systems


The present invention relates to novel expression cassettes and vectors for efficiently producing authentic recombinant human proteins from stable cultures of novel human cell lines, the authentic recombinant proteins produced therefrom, and antibodies raised against those authentic recombinant proteins.. .
Humanzyme Limited
04/09/15
20150099278

Polynucleotides encoding antibodies


The present invention relates to antagonizing the activity of il-17a, il-17f and il-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for il-17a and il-17f and a binding entity that binds il-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same..
Bristol-myers Squibb Company
04/09/15
20150098965

Materials and methods for detecting, preventing, and treating retroviral infection


The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that fiv can be transmitted from cats to humans and that the fiv can infect human cells in vivo and that antibodies generated by the infected person cross-react with hiv antigens.
University Of Florida Research Foundation, Inc.
04/09/15
20150098949

Vegf/dll4 binding agents and uses thereof


The present invention relates to vegf-binding agents, dll4-binding agents, vegf/dll4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human vegf, antibodies that specifically bind human dll4, and bispecific antibodies that specifically bind human vegf and/or human dll4.
Oncomed Pharmaceuticals, Inc.
04/09/15
20150098948

Compositions and methods for the therapy and diagnosis of influenza


The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection..
Theraclone Sciences, Inc.
04/09/15
20150098947

Monoclonal olfml-3 antibodies and uses thereof


Provided herein are monoclonal antibodies against olfml-3. In some aspects, methods for treating angiogenesis-related conditions, such as cancer, are provided comprising administering an olfml-3-binding antibody of the embodiments..
Research Development Foundation
04/09/15
20150098939

Novel antagonist antibodies and their fab fragments against gpvi and uses thereof


The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein glycoprotein vi (gpvi) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a gpvi depletion phenotype.
Sanofi
04/09/15
20150098936

Reimmunization and antibody design


The present invention relates to methods for harvesting of antibodies from an antibody library. The antibodies are harvested by utilising a certain epitope that is analogous to the epitope of the antigen used for immunization but that may differ in global physical and biochemical properties allowing the production of antibodies against antigens that normally cannot be utilised as immunizing agents.
Carviar Aps
04/09/15
20150098935

Induction of highly specific antibodies to a hapten but not to a carrier peptide by immunization


In this application is described a composition and method for inducing in a subject anti-hapten antibodies without inducing antibodies to the carrier protein. Kits for designing and making compositions with desired haptens are also described.
Walter Reed Army Institute Of Research
04/09/15
20150098900

Anti-fcrh5 antibodies


The invention provides anti-fcrh5 antibodies and immunoconjugates and methods of using the same.. .
Genentech, Inc.
04/02/15
20150096077

Plants with improved nitrogen utilization and stress tolerance


The present invention relates to transgenic plants that have increased nitrogen use efficiency, stress tolerance, or both and that have been transformed using a novel vector construct including nucleic acid sequences that modulate nitrogen use in plants. In various embodiments, the vector construct includes one or more nucleic acid sequences selected from the group consisting of seq id no: 2, 4, 7, 9, 11, 13, 15, 17, 22, 24, 26, 28, 30, 32, 34, 36, or 38.
Iowa Corn Promotion Board
04/02/15
20150094454

Antibodies that bind cell-associated ca 125/o772p


The present invention provides antibodies, and antigen-binding fragments of antibodies, fusion polypeptides and analogs that preferentially bind cell-associated ca 125/o772p polypeptides relative to shed ca 125/o772p polypeptides. The present invention further provides methods of preventing, managing, treating or ameliorating one or more symptoms associated with a ca 125/o772p-related disorder.
Purdue Pharma L.p.
04/02/15
20150094451

Readily isolated bispecific binding molecules with native format having mutated constant regions


The invention provides heterodimer bispecific antigen-binding molecules that include a first polypeptide that does not include an igg ch1 domain and a second polypeptide having an immunoglobulin constant region where there is at least one mutation in the igg ch3 domain that abolishes the ability of the second polypeptide to bind ch3-specific affinity media such that the first and second polypeptides have different affinities with respect to ch1 and ch3 specific affinity reagents that allows rapid isolation by differential binding of the first and second polypeptides to these affinity reagents. The invention also provides bispecific antibodies that have igg ch1 and ch3 regions with different affinities with respect to affinity reagents that allows rapid isolation by differential binding of the igg regions to these affinity reagents.
Novimmune S.a.
04/02/15
20150094218

Method and kit for detection of anti-beta amyloid antibodies


An in vitro method and a kit for the quantification of antibodies anti-beta amyloid protein in a sample of cerebrospinal fluid comprising the following steps a) concentrating the quantity of said antibodies of said sample with magnetic micro beads coated with macromolecules capable of binding said antibodies b) analysing the concentrated sample obtained in step a) by immunoenzyme assay or by radioimmunoassay; c) analysing a sample comprising antibodies anti-beta amyloid protein having a known titre with the same assay used in step b) and elaborating the related calibration curve, wherein said antibody having a known titre is a murine antibody belonging to the igg2a or igg2b class or a human or humanized antibody belonging to the igg2b or iggi class.. .
UniversitÀ Degli Studi Di Milano - Bicocca
04/02/15
20150093799

Histidyl-trna synthetases for treating autoimmune and inflammatory diseases


The present invention relates generally to compositions and methods comprising histidyl-trna synthetase polypeptides or other specific blocking agents for the treatment autoimmune diseases and other inflammatory diseases, including those related to jo-1 antibodies.. .
Atyr Pharma, Inc.
04/02/15
20150093787

Compositions and methods for use in recombinational cloning of nucleic acids


The present invention relates generally to compositions and methods for use in recombinational cloning of nucleic acid molecules. In particular, the invention relates to nucleic acid molecules encoding one or more recombination sites or portions thereof, to nucleic acid molecules comprising one or more of these recombination site nucleotide sequences and optionally comprising one or more additional physical or functional nucleotide sequences.
Life Technologies Corporation
04/02/15
20150093783

Humanized antibodies to ca215


Provided herein are humanized forms of murine rp215 monoclonal antibodies and methods of using the same. These humanized rp215 monoclonal antibodies were characterized in terms of their respective affinity and specificity to the corresponding tumor-associated antigen, ca215, and shown to be comparable to those of murine rp215..
Vancouver Biotech Ltd.
04/02/15
20150093768

Detection of prostate and bladder cancer


The present invention relates to a method for the diagnosis, prognosis, and monitoring of cancer, such as early or late stage prostate cancer and bladder cancer, in a subject by detecting bcl-2 in a biological sample from the subject, preferably a urine or blood sample. Bcl-2 may be measured using an agent that detects or binds to bcl-2 protein or an agent that detects or binds to encoding nucleic acids, such as antibodies specifically reactive with bcl-2 protein or a portion thereof.
University Of South Florida
04/02/15
20150093759

Compositions and methods for detecting nitration of pkg-1a and methods of use thereof


antibodies for detecting nitration of nitrotyrosine 247 pkg-1α and antibodies for detecting nitrotyrosine 425 of pkg-1α are disclosed. Methods of detecting nitrotyrosine 247 pkg-1α and nitrotyrosine 425 of pkg-1α, and uses thereof are also disclosed for identification and diagnosis or phenotypes, pathologies, diseases and disorders associated with protein nitration of pkg-1α are also disclosed.
Georgia Regents Research Institute, Inc.
04/02/15
20150093742

Antibodies for oncogenic strains of hpv and methods of their use


The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to e6 proteins from at least three oncogenic strains of hpv. In general, the antibodies bind to amino acids motifs that are conserved between the e6 proteins of different hpv strains, particularly hpv strains 16 and 18.
Arbor Vita Corporation
04/02/15
20150093408

Lyme disease vaccine, genetic construct, recombinant protein, designing genetic construct, producing vaccine, producing recombinant proteins, use of recombinant proteins in the production of lyme disease vaccine


The present invention relates to a lyme disease vaccine, a genetic construct, recombinant protein, method for genetic construct design, method for vaccine delivery, method for recombinant proteins delivery, use of recombinant proteins in the production of lyme disease vaccine. In particular, the method concerns the use of trospa and trospa-salp15 recombinant proteins derived from castor bean tick (ixodes riccinus) as a component of lyme disease vaccine for animals.
Instytut Chemii Bioorganicznej Pan
04/02/15
20150093403

Canine circovirus sequences and uses thereof


The invention is directed to a isolated a canine circoviruses associated with canine respiratory and gastrointestinal disease, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to antibodies against antigens from canine circoviruses.
The Trustees Of Columbia University In The City Of New York
04/02/15
20150093395

Anti-fxi antibodies and methods of use


Disclosed herein are monoclonal antibodies specific for factor xi (fxi) that prevent activation of fxi by factor xiia (fxiia). The monoclonal antibodies are universal fxi antibodies, capable of binding all mammalian species tested.
Oregon Health & Science University
04/02/15
20150093394

Formulation of human antibodies for treating tnf-alpha associated disorders


A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a ph of between about 4 and about 8, and enhanced stability.. .
Abbvie Biotechnology Ltd
04/02/15
20150093392

Antibodies


The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to cdh17 with high affinity. Nucleic acid molecules encoding cdh17 antibodies, expression vectors, host cells and methods for expressing cdh17 antibodies are also provided.
Oxford Bio Therapeutics Ltd
04/02/15
20150093390

Humanized and chimeric anti-factor bb antibodies and uses thereof


A method of inhibiting complement activation mediated by bb inhibitors in a subject includes administering a bb inhibitor to the subject to inhibit at least one of bb binding to factors b and properdin, inhibit c3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of c3a, c5a, and mac.. .
Novelmed Theraperutics, Inc.
04/02/15
20150093389

Clostridium difficile antigens


The present invention relates to recombinant clostridium difficile antigens based on a polypeptide, consisting of or comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence consisting of residues 1500-700 of a c. Difficile toxin a sequence or a c.
The Secretary Of State For Health
04/02/15
20150093388

Antibodies and assays for detection of folate receptor 1


The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided..
Immunogen, Inc.
04/02/15
20150093385

Recombinant antibodies having dual specificity for gangliosides and use thereof


The present invention relates to new monoclonal antibodies and fragments of these antibodies, which have dual specificity and high affinity for n-acetyl gm3 and n-glycolyl gm3 and do not recognize other gangliosides. In another aspect, the present invention relates to the use of these antibodies and their fragments in the therapy of tumors characterized by a significant expression of any of the two antigens recognized by these antibodies, or a mixed expression of both antigens.
Centro De Inmunologia Molecular
04/02/15
20150093381

Fixed dosing of her antibodies


The present invention concerns fixed dosing of her antibodies, such as pertuzumab.. .
Genentech, Inc.
04/02/15
20150093336

Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages


The disclosure relates to immunoglobulin single variable domains directed against human macrophage mannose receptor (mmr) and their uses in the field of oncology. More specifically, it concerns immunoglobulin single variable domains, including single-domain antibodies (sdabs), against human mmr and their use in targeting and in vivo imaging of tumor-associated macrophages, with applications in the field of cancer diagnostics and therapeutics and monitoring of the disease..
Vrije Universiteit Brussel
03/26/15
20150089680

Human lambda light chain mice


Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.
03/26/15
20150087814

Chemoenzymatic glycoengineering of antibodies and fc fragments thereof


The present invention provides for recombinant endo-s mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated glcnac-protein acceptor. Such recombinant endo-s mutants are useful for efficient glycosylation remodeling of iggl-fc domain to provide different antibody glycoforms carrying structurally well-defined fc n-glycans..
University Of Maryland, Baltimore
03/26/15
20150087812

Human autotaxin antibodies and methods of use


antibodies and compositions capable of binding and, in a particular aspect, inhibiting the lysophosphatidylipase d activity of human autotaxin protein. The antibodies or are useful in detecting human autotaxin protein and treating diseases and disorders associated with unwanted lysophosphatidylipase d and the presence of lysophosphatidic acid, such as cancer and pulmonary diseases..
Janssen Biotech, Inc.
03/26/15
20150087810

Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof


The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one matrix metalloprotease (mmp), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one mmp protease, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one mmp protease in a variety of therapeutic, diagnostic and prophylactic indications.. .
Cytomx Therapeutics, Inc.
03/26/15
20150087806

Glycopeptide and uses thereof


A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof..
University Of Georgia Research Foundation, Inc.
03/26/15
20150087000

Diagnostic kits to detect sp22 and sp22 antibodies


Oral, topical and injectable contraceptives, which are based on sperm protein 22 kda (sp22) polypeptides and antibodies and infertility diagnostics and kits are provided.. .
U.s. Environmental Protection Agency
03/26/15
20150086991

Uses of anti-cd40 antibodies


The methods of the present invention find use in treatment of cancers and pre-malignant conditions that are associated with cd40-expressing cells. These methods are particularly advantageous with respect to cancers and pre-malignant conditions that are associated with cells expressing both cd40 and cd20, as the methods enable the treatment of patients having a cancer or pre-malignant condition that is refractory to therapy with other oncotherapeutic agents such as anti-cd20 antibodies..
03/26/15
20150086978

Methods and materials for the detection of dengue virus infection


The present invention provides monoclonal antibodies that are specific for the dengue non-structural glycoprotein ns1 in monomeric and/or oligomeric (primarily dimeric) form, together with methods, including elisa and lateral flow assays, that employ the disclosed antibodies for the early detection of dengue virus infection. Diagnostic kits for the detection of dengue infection are also provided, such kits including the disclosed monoclonal and/or polyclonal antibodies..
Inbios International, Inc.
03/26/15
20150086581

Fast diagnosis and personalized treatment for acne


Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses rt4, rt5, rt7, rt8, rt9, or rt10. Methods for treating acne include administering an effective amount of a drug specifically targeting rt4, rt5, rt7, rt8, rt9, or rt10, such as small molecules, antisense molecules, sirnas, biologics, antibodies, phages, vaccines, or combination thereof..
The Regents Of The University Of California
03/26/15
20150086578

Human cytomegalovirus vaccine


Combination peptides, polypeptides and proteins that elicit high titer neutralizing antibodies against cytomegalovirus (cmv) are provided. The combination peptides, polypeptides and proteins encompass epitopes located within the ul130 and ul131 components of the gh/gl/ul128-131 protein complex, in particular, epitopes located within amino acid residues 27-46 of ul130 and amino acid residues 90-106 of ul131.
Virginia Commonwealth University
03/26/15
20150086577

Pathogenic phlebovirus isolates and compositions and methods of use


Described herein are the clinical and laboratory characteristics of two patients bitten by ticks and infected with a unique member of the genus phlebovirus (family bunyaviridae) with a proposed name of heartland virus (hrtlv). Provided herein are nucleotide and amino acid sequences of the phlebovirus isolates, primers and probes that specifically hybridize with the phlebovirus isolates, and antibodies specific for the phlebovirus proteins.
The Government Of The United States Of America As Represented By The Secretary Of The Department Of
03/26/15
20150086576

Sortase-modified vhh domains and uses thereof


In some aspects, polypeptides comprising single domain antibodies and methods of identifying single domain antibodies are provided. In some embodiments polypeptides comprising a single domain antibody and a sortase recognition sequence, are provided.
Whitehead Institute For Biomedical Research
03/26/15
20150086575

B cell surface reactive antibodies


The invention relates to antibodies that are reactive to the cell surface of cd19+ b cells, including b-cell chronic lymphocytic leukemia (b-cll) cells, and compositions and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with cd19+ b cells, such as b-cll.. .
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
03/26/15
20150086574

Antibodies that specifically bind to tim3


Provided herein are antibodies specific for tim3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation..
Cellerant Therapeutics, Inc.
03/26/15
20150086568

Anti-vegf antibodies


The invention herein provides isolated antibodies that bind to vegf. The invention further provides methods of making anti-vegf antibodies, and polynucleotides encoding anti-vegf antibodies..
Genentech, Inc.
03/26/15
20150086564

Novel antibodies anti-spla2-iia and uses thereof


The present invention relates to antibodies anti-spla2-iia and uses thereof.. .
Universite Nice Sophia Antipolis
03/26/15
20150086562

Anti-cd22 antibodies


Anti-cd22 antibodies, including isolated nucleic acids that encode at least one such anti-cd22 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof including therapeutic compositions, methods and devices.. .
Bioatla, Llc
03/26/15
20150086561

Binding moieties for biofilm remediation


Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human b lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described.
Trellis Bioscience, Llc
03/26/15
20150086560

Influenza vaccine and therapy


The present invention is directed generally to m1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-m1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-m1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response..
Engen Bio Inc.
03/26/15
20150086559

Antibody formulation


Anti-cd40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation.
Novartis Ag
03/26/15
20150086558

Anti-mige antibodies that bind to the junction between ch4 and cemx domains


antibodies binding to junction regions between the ch4 and cεmx domains of membrane-bound ige and uses thereof in treating ige-mediated diseases such as allergic diseases.. .
Academia Sinica
03/26/15
20150086556

Anti-activin a antibodies and uses thereof


The disclosure provides compositions and methods relating to or derived from anti-activin a binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin a antibodies that bind human activin a, activin a-binding fragments and derivatives of such antibodies, and activin a-binding polypeptides comprising such fragments.
Amgen Inc.
03/26/15
20150086555

Anti-hemagglutinin antibody compositions and methods of use thereof


The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection..
Theraclone Sciences, Inc.
03/26/15
20150086552

Bispecific antibodies and methods of using the same


The present invention relates to antagonizing the activity of il-17a, il-17f and il-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for il-17a and il-17f and a binding entity that binds il-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same..
Bristol-myers Squibb Company
03/26/15
20150086550

Combination of the application of antibodies for immunostimulation together with glucocorticoids


The present invention relates to methods for reducing or eliminating the non-specific release of a cytokine associated with a disease comprising administering at least one glucocorticoid and an immunostimulating antibody. Additionally, the present invention relates to a pharmaceutical composition that contains at least one immunostimulating antibody and at least one glucocorticoid..
03/26/15
20150086546

Humanized anti-ccr2 antibodies and methods of use therefor


The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) cc-chemokine receptor 2 (ccr2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian ccr2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods..
Millennium Pharmaceuticals, Inc.
03/26/15
20150086540

Methods of using an antibody to inhibit wnt-mediated cardiac remodeling


The present invention is directed to monoclonal antibodies and fragments thereof directed to lrp5/6 that find use in the prevention and treatment of cardiac remodeling and cancer. Also disclosed are methods for using such monoclonal antibodies in the prevention and treatment of such diseases..
Vanderbilt University
03/26/15
20150086483

Methods for treating idiopathic pulmonary fibrosis


The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (iff) by administering anti-ctgf antibodies. Methods for prognosing individuals with ipf are also provided..
Fibrogen, Inc.
03/26/15
20150086478

Humanized pan-her antibody compositions


The invention relates to humanized recombinant antibodies targeting the egfr family receptors egfr, her2 and her3, compositions comprising at least one humanized anti-egfr antibody, at least one humanized anti-her2 antibody and at least one humanized anti-her3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple egfr-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies..
Symphogen A/s


Popular terms: [SEARCH]

Antibodies topics: Antibodies, Recombinant, Nucleic Acid, Nucleic Acids, Polypeptide, Therapeutics, Immunoglobulin, Immunoglobulins, Monoclonal, Radiation Therapy, Desmoplastic, Hypertension, Hypertensive, Immunotherapy, Photodynamic Therapy

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antibodies for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibodies with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         















1.1099

4185

2 - 1 - 90